Your browser is no longer supported. Please, upgrade your browser.
Axcella Health Inc.
Index- P/E- EPS (ttm)-1.71 Insider Own0.50% Shs Outstand38.20M Perf Week-2.03%
Market Cap114.03M Forward P/E- EPS next Y-1.70 Insider Trans0.00% Shs Float31.54M Perf Month-8.52%
Income-61.90M PEG- EPS next Q-0.39 Inst Own61.90% Short Float1.38% Perf Quarter-15.20%
Sales- P/S- EPS this Y49.90% Inst Trans-1.00% Short Ratio3.39 Perf Half Y-9.09%
Book/sh0.93 P/B3.12 EPS next Y-21.20% ROA-69.90% Target Price12.62 Perf Year-48.67%
Cash/sh1.68 P/C1.72 EPS next 5Y0.00% ROE-112.20% 52W Range2.75 - 6.84 Perf YTD-44.12%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.60% Beta-
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low5.45% ATR0.18
Employees59 Current Ratio8.70 Sales Q/Q- Oper. Margin- RSI (14)42.91 Volatility3.75% 4.65%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.40% Profit Margin- Rel Volume0.40 Prev Close2.97
ShortableYes LT Debt/Eq0.70 EarningsNov 11 BMO Payout- Avg Volume128.68K Price2.90
Recom2.00 SMA20-6.44% SMA50-4.14% SMA200-25.32% Volume51,191 Change-2.36%
Oct-12-21Initiated Noble Capital Markets Outperform $6
Sep-22-21Downgrade Goldman Buy → Neutral $9 → $5
Jul-30-21Downgrade JP Morgan Neutral → Underweight
Jul-06-21Initiated H.C. Wainwright Buy $14
Jun-03-21Resumed Chardan Capital Markets Buy $10 → $16
Nov-18-20Initiated ROTH Capital Buy $28
Oct-27-20Initiated Chardan Capital Markets Buy $16
Sep-25-20Initiated B. Riley FBR Buy $14
Jul-31-20Initiated Piper Sandler Overweight $25
May-28-20Initiated Wedbush Outperform $28
May-01-20Initiated BTIG Research Buy $10
Jun-03-19Initiated SVB Leerink Outperform $21
Jun-03-19Initiated JP Morgan Overweight $20
Jun-03-19Initiated Goldman Buy $25
Nov-18-21 07:58AM  
Nov-15-21 07:39AM  
Nov-10-21 08:42AM  
Nov-02-21 07:58AM  
Oct-26-21 07:47PM  
Oct-19-21 07:58AM  
Oct-13-21 10:00AM  
Oct-05-21 07:58AM  
Sep-28-21 10:57AM  
Sep-09-21 09:49AM  
Sep-07-21 07:58AM  
Sep-02-21 06:43AM  
Aug-30-21 01:21PM  
Aug-16-21 07:58AM  
Jul-29-21 07:28AM  
Jul-22-21 07:28AM  
Jun-30-21 07:28AM  
Jun-13-21 10:15AM  
Jun-10-21 11:35AM  
May-25-21 06:00AM  
May-24-21 07:28AM  
May-19-21 09:01AM  
May-13-21 02:05AM  
May-11-21 07:55AM  
May-06-21 07:28AM  
Apr-27-21 07:28AM  
Apr-22-21 07:28AM  
Apr-14-21 08:50AM  
Apr-13-21 07:28AM  
Apr-09-21 09:19AM  
Mar-30-21 09:30AM  
Mar-18-21 10:01AM  
Mar-17-21 07:28AM  
Mar-10-21 08:00AM  
Mar-03-21 04:20PM  
Feb-25-21 07:55AM  
Feb-18-21 07:55AM  
Feb-11-21 11:53PM  
Jan-11-21 07:58AM  
Jan-05-21 07:58AM  
Nov-26-20 08:03PM  
Nov-20-20 07:30AM  
Nov-14-20 07:34AM  
Nov-13-20 07:30AM  
Nov-12-20 07:30AM  
Nov-11-20 09:14AM  
Oct-29-20 08:00AM  
Oct-07-20 10:49AM  
Oct-02-20 07:58AM  
Sep-30-20 07:28AM  
Sep-29-20 07:58AM  
Sep-24-20 03:35PM  
Sep-08-20 08:00AM  
Aug-27-20 08:00AM  
Aug-20-20 07:30AM  
Aug-17-20 07:30AM  
Aug-13-20 08:49AM  
Aug-11-20 10:19AM  
Aug-07-20 09:53AM  
Aug-05-20 10:41AM  
Aug-03-20 08:00AM  
Jul-27-20 10:25AM  
Jul-15-20 11:30AM  
Jul-09-20 09:42AM  
Jul-07-20 08:00AM  
Jul-01-20 08:03AM  
Jun-24-20 12:00PM  
Jun-22-20 11:02PM  
Jun-17-20 09:50AM  
Jun-15-20 10:59AM  
Jun-12-20 10:23AM  
Jun-11-20 10:44PM  
Jun-03-20 08:00AM  
Jun-02-20 11:30AM  
Jun-01-20 12:09PM  
May-28-20 08:00AM  
May-22-20 06:21AM  
May-18-20 04:05PM  
May-15-20 11:30AM  
May-13-20 10:31PM  
May-11-20 08:00AM  
May-06-20 08:00AM  
May-05-20 04:05PM  
May-04-20 04:05PM  
Apr-29-20 11:30AM  
Apr-20-20 08:53AM  
Apr-07-20 08:00AM  
Mar-30-20 12:00PM  
Mar-23-20 04:01PM  
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pisano Gary P.DirectorAug 13Option Exercise0.2881,43322,80181,433Aug 25 04:32 PM
Chakravarthy ManuSVP & Chief Medical OfficerFeb 01Sale5.5018,472101,63141,528Feb 03 08:22 PM